HIV/AIDS Research and Interventions

Modeling of HIV-1 prophylactic efficacy and toxicity with islatravir shows non-superiority for oral dosing, but promise as a subdermal implant

This paper models the efficacy and toxicity of islatravir as oral and subdermal PrEP, finding implants offer safer efficacy while oral dosing has toxicity risks.